BOT 1.35% 37.5¢ botanix pharmaceuticals ltd

BOT - Anything but charting, page-10570

  1. 3,547 Posts.
    lightbulb Created with Sketch. 897
    Whilst this is true, I've always seen the advancement of SB to be favourable as it only creates further exposure for Botanix as a whole.

    It may even make things easier as we start to apply for Sofdra approvals throughout territories which Kaken do not manage. Also provides us with a case study to sell licensing in areas we might not want to actively control/manage ourselves..

    Just my opinion
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.